| Item 1. | Security and Issuer |
| (a) | Title of Class of Securities:
Ordinary Shares, par value NIS 1.5 per share |
| (b) | Name of Issuer:
CollPlant Biotechnologies Ltd |
| (c) | Address of Issuer's Principal Executive Offices:
4 Oppenheimer St, Weizmann Science Park, Rehovot,
ISRAEL
, 7670104. |
| Item 2. | Identity and Background |
|
| (a) | The Waterproof Partnership, Ltd., The Loewenbaum 1992 Trust, The Loewenbaum Residence Trust FBO Anna Loewenbaum and The Elizabeth Scott Loewenbaum 1992 Trust are collectively referred to as the "Reporting Entities" and each as a "Reporting Entity." George Walter Loewenbaum, Elizabeth S. Loewenbaum and Lilian S. Loewenbaum are referred to herein as the "Individual Filers" and each, an "Individual Filer". The Individual Filers and the Reporting Entities are collectively referred to herein as the "Reporting Persons".
The Waterproof Partnership, Ltd., a holding company, is a Texas limited partnership, with George Walter Loewenbaum and Lilian S. Loewenbaum serving as general partners. The Loewenbaum 1992 Trust, a holding company, is a Texas trust, with George Walter Loewenbaum and Lilian S. Loewenbaum serving as trustees. The Loewenbaum Residence Trust FBO Anna Loewenbaum, a holding company, is a Texas trust, with George Walter Loewenbaum and Lilian S. Loewenbaum serving as trustees. The Elizabeth Scott Loewenbaum 1992 Trust, a holding company, is a Texas trust, with George Walter Loewenbaum and Lilian S. Loewenbaum serving as trustees. |
| (b) | The address of each Reporting Person is 1000 Westbank Dr, Ste #2A, Austin, TX 78746. George Walter Loewenbaum, Elizabeth S. Loewenbaum and Lilian S. Loewenbaum are citizens of the United States and their current occupations are individual private investors. |
| (c) | Refer (b) above |
| (d) | During the last five years, none of the Reporting Persons nor any general partner or trustee of the Reporting Entities (a) has been convicted in a criminal proceeding (excluding traffic violations and similar misdemeanors), or (b) was a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violations with respect to such laws. |
| (e) | Refer (d) above |
| (f) | Refer (b) above |
| Item 3. | Source and Amount of Funds or Other Consideration |
| | The information concerning the ownership of Ordinary Shares of the Reporting Persons set forth on the cover pages hereto is expressly incorporated by reference herein. |
| Item 4. | Purpose of Transaction |
| | The acquisitions of Ordinary Shares by the Reporting Persons for investment purposes.
While the Reporting Persons do not have any present plans or proposals that relate to or would result in any of the actions specified in clauses (a) through (j) of Item 4 of Schedule 13D, the Reporting Persons intend to review their investment in the Issuer on a continuing basis and, depending upon the price of and other market conditions relating to the Ordinary Shares or other securities of the Issuer, subsequent developments affecting the Issuer, the Issuer's business and prospects, other investment and business opportunities available to the Reporting Persons, general stock market and economic conditions, tax considerations, and other factors deemed relevant, may form a plan or proposal to take any of the actions specified in clauses (a) through (j) of Item 4 of Schedule 13D, in which case the Reporting Persons will file an amendment to this Schedule 13D. |
| Item 5. | Interest in Securities of the Issuer |
| (a) | The information concerning the ownership of Ordinary Shares of the Reporting Persons set forth on the cover pages hereto is expressly incorporated by reference herein. To the best knowledge of the Reporting Persons, as of June 30, 2025, there were 12,716,014 Ordinary Shares outstanding (which number was set forth in the Issuer's Form 6-K filed by the Issuer with the SEC on August 20, 2025). The calculations of percentages in this Schedule 13D are based on the number of shares of Ordinary Shares outstanding on June 30, 2025 plus the shares that may be issued to the Reporting Persons within 60 days upon the exercise of options and warrants.
Collectively, the Reporting Persons beneficially own in the aggregate 1,698,533 Ordinary Shares, representing 13.4% of the total outstanding Ordinary Shares (including the shares that may be issued to the Reporting Persons within 60 days upon the exercise of options and warrants). |
| (b) | The information concerning the ownership of Ordinary Shares of the Reporting Persons set forth on the cover pages hereto is expressly incorporated by reference herein. |
| (c) | During the past sixty days, the Reporting Persons have not effected any transactions involving the Ordinary Shares except for the following:
* The Loewenbaum Residence Trust FBO Anna Loewenbaum purchased 200 Ordinary Shares underlying ADSs on the open market on July 28, 2025 for $2.33 per share;
* The Elizabeth Scott Loewenbaum 1992 Trust purchased 300 Ordinary Shares underlying ADSs on the open market on July 28, 2025 for $2.29 per share; and
* George Walter Loewenbaum purchased: (a) 4,206 Ordinary Shares underlying ADSs through the Walter Loewenbaum Trust on the open market on July 29, 2025 at a weighted average price of $2.41 per share; (b) 1,668 Ordinary Shares underlying ADSs directly on the open market July 30, 2025 for $2.31 per share; (c) 1,200 Ordinary Shares underlying ADSs through an IRA on the open market on July 25, 2025 for $2.27 per share; (d) 4,700 Ordinary Shares underlying ADSs through an IRA on the open market on July 28, 2025 for a weighted average price per share of $2.25; (e) 9,739 Ordinary Shares underlying ADSs through an IRA on the open market on July 30, 2025 for a weighted average price per share of $2.38; and (f) 139 Ordinary Shares underlying ADSs through an IRA on the open market on July 31, 2025 for $2.37 per share. |
| (d) | Except as listed in Item 5(a), to the best knowledge of the Reporting Persons, no person other than the Reporting Persons has the right to receive, or the power to direct the receipt of dividends from, or the power to direct the receipt of proceeds of the sale of the shares of Common Stock beneficially owned by the Reporting Persons. |
| (e) | not applicable |
| Item 6. | Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer |
| | The Reporting Persons have entered into a Joint Filing Agreement, dated January 28, 2025, a copy of which is attached hereto as Exhibit 1 to this Schedule 13D and is incorporated herein by reference. |
| Item 7. | Material to be Filed as Exhibits. |
| | 1. Joint Filing Agreement dated January 28, 2025 (incorporated by reference to Exhibit A to the Schedule 13G/A filed by the Reporting Persons on January 28, 2025). |
